Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.
Neal Shore, MD, FACS: Let’s stick with the theme of high-risk prostate cancer. And Steven, this is your case.
Steven Finkelstein, MD, DABR, FACRO: This is a patient with high-risk prostate cancer. It’s a 74-year-old gentleman with a history of chronic prostatitis. His PSA [prostate-specific antigen] was 6.5 ng/ml, and a biopsy was done, and it showed prostate adenocarcinoma Gleason score of 8 with perineural invasion. An MRI was done and showed a 0.9 cm lesion, a technetium-99m bone scan was done, and that showed a focal radiotracer in the lateral left 9th rib. It’s important for the audience that when you see things on bone scan, it should also correlate that with a clinical question, which is, did you ever fall? Did you ever break something? Do you ever have an issue? He had a CT [scan], which showed a nonaggressive appearing reticular density in the left 9th rib. Most compatible with a benign fibro-osseous lesion, which he happened to be told about years before. Now, what are you going to do for this guy? Would you also order a PSMA [prostate-specific membrane antigen] PET [positron emission tomography]?
Neal Shore, MD, FACS: Mike, what would you do here? I’m thinking yes, but I’ll defer to your experience.
Michael Gorin, MD: I would’ve started with the PSMA PET and foregone the technetium-99m bone scan and the CT because in the NCCN [National Cancer Comprehensive Network] guidelines it now states that you do not require conventional imaging prior to triggering ordering a PSMA PET scan. For me, high-risk disease equals reflexive PSMA-PET scan. But in this case, given what we know, certainly, I would order a PSMA-PET scan in this context as well.
Lawrence Saperstein, MD: It brings up a great point of educating the community who’s going to be ordering these scans because it looks like we’re falling back into the conventional workup of a CT and a bone scan in this patient. And we can look at the pictures and see what we see.
Neal Shore, MD, FACS: But that’s an important point. Take-home message. And now that the guidelines are saying that you do not have to get conventional CT scan and technician bone scan prior to getting a PSMA PET, I think we all agree with that.
Transcript edited for clarity.
FDA greenlights phase 3 study of LAE201 in mCRPC
May 23rd 2024"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 pivotal trial design has been discussed with the US FDA and the approval for the protocol has been received this month," said Yong Yue, MD, PhD.
Galen Prostate shows potential to enhance prostate cancer detection
May 20th 2024"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.